Asimenia Angelidou to Adjuvants, Immunologic
This is a "connection" page, showing publications Asimenia Angelidou has written about Adjuvants, Immunologic.
Connection Strength
0.286
-
Violari A, Otwombe K, Hahn W, Chen S, Josipovic D, Baba V, Angelidou A, Smolen KK, Levy O, Mkhize NN, Woodward Davis AS, Martin TM, Haynes BF, Williams WB, Sagawa ZK, Kublin JG, Polakowski L, Brewinski Isaacs M, Yen C, Tomaras G, Corey L, Janes H, Gray GE. Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns. J Clin Invest. 2025 Jun 02; 135(11).
Score: 0.203
-
Nanishi E, Angelidou A, Rotman C, Dowling DJ, Levy O, Ozonoff A. Precision Vaccine Adjuvants for Older Adults: A Scoping Review. Clin Infect Dis. 2022 08 15; 75(Suppl 1):S72-S80.
Score: 0.042
-
Diray-Arce J, Angelidou A, Jensen KJ, Conti MG, Kelly RS, Pettengill MA, Liu M, van Haren SD, McCulloch SD, Michelloti G, Idoko O, Kollmann TR, Kampmann B, Steen H, Ozonoff A, Lasky-Su J, Benn CS, Levy O. Bacille Calmette-Gu?rin vaccine reprograms human neonatal lipid metabolism in?vivo and in?vitro. Cell Rep. 2022 05 03; 39(5):110772.
Score: 0.041